Latest Enzyme (MLN) News Update

Deep Dive

1. @CoinMarketCap: Bybit Delists MLN Perpetual Futures bearish

"Bybit... will delist perpetual futures contracts for... Enzyme (MLN)... at 11:30 a.m. UTC on June 26. All open positions... will be automatically closed..." – CoinMarketCap (N/A followers · N/A impressions · 2026-06-24 12:20 UTC) View original post What this means: This is bearish for MLN because it reduces market depth, limits leveraged trading options, and signals waning exchange confidence, which can trigger further selling pressure from position closures.

2. @enzymefinance: Joins Canton Network for Q3 Launch bullish

"Enzyme is now a member of the @CantonFdn 🎉 We're looking forward to... bringing Onyx and Myso natively to @CantonNetwork in Q3." – @enzymefinance (36.8K followers · N/A impressions · 2026-05-22 14:04 UTC) View original post What this means: This is bullish for MLN as it demonstrates active development and expands the protocol's reach into institutional tokenized finance, potentially driving future usage and demand for the MLN token.

3. Adanigj: Historical Volatility and Recent Surge mixed

"Enzyme (MLN) changed by +1.4 percent (to 5.08 USDT) in the last 30 minutes on Binance Futures... Trade now for bumper profits" – @Adanigj (1,455 followers · N/A impressions · 2025-12-26 06:33 UTC) What this means: This older data highlights MLN's inherent volatility. The token's recent 24-hour surge of 10.13% to $1.45 (3 July 2026) is a sharp rebound, but it comes after a -79.72% drop over the past year, indicating highly speculative and fragile sentiment.

Conclusion

The consensus on MLN is mixed, caught between negative exchange actions and positive long-term development. While the Bybit delisting and prior Binance removal (May 2026) severely hurt liquidity, the team's focus on institutional partnerships like Canton Network offers a counter-narrative for future utility. Watch trading volume on remaining exchanges closely to gauge if the recent price bounce can sustain without major platform support.

Deep Dive

1. Bybit Delists MLN Perpetual Futures (24 June 2026)

Overview: Bybit announced the delisting of perpetual futures contracts for Enzyme (MLN), Solv (SOLV), and Mobox (MBOX), effective June 26, 2026. All open positions were automatically closed at market price. Exchanges typically take such action after periodic reviews of liquidity, trading volume, and project development. What this means: This is bearish for MLN because it reduces avenues for leveraged trading and is a clear signal from a major platform that the asset no longer meets its performance criteria, which can deter other traders and exchanges. (BitcoinWorld)

2. Binance Completes MLN Spot Delisting (27 May 2026)

Overview: Following an April 2026 "Monitoring Tag" warning, Binance formally delisted MLN and four other altcoins from all spot, margin, and futures services. The announcement on May 13, 2026, triggered an immediate 18% price decline for MLN. What this means: This is significantly bearish as it drastically reduces liquidity and mainstream accessibility, often leading to sustained selling pressure and reputational damage as investors exit positions before withdrawal deadlines. (CoinMarketCap)

3. Enzyme Joins Rayls as Launch Partner (8 May 2026)

Overview: The Enzyme protocol announced a partnership with Rayls Labs, making its Onyx (vault infrastructure) and Myso (on-chain options) products available on the Rayls network from day one. What this means: This is a bullish counterpoint for the underlying protocol, demonstrating continued development and institutional-grade adoption in the tokenized finance space, which could support long-term utility independent of exchange listings. (Enzyme)

Conclusion

Enzyme is navigating a stark divergence: its core protocol is forging new institutional partnerships while its token faces severe headwinds from exchange delistings. Will underlying utility and new integrations eventually outweigh the loss of major trading venues?

Deep Dive

1. Native Integration with Canton Network (Q3 2026)

Overview: Enzyme has joined the Canton Network and plans to bring its Onyx (tokenization layer) and Myso (on-chain options protocol) products natively to this ecosystem in Q3 2026. The Canton Network is a privacy-enabled blockchain designed for institutional finance, allowing compliant interoperability between applications. This integration aims to position Enzyme's infrastructure within a regulated environment attractive to traditional asset managers.

What this means: This is bullish for MLN because it directly targets institutional adoption, a key growth vector for tokenized asset management. Success here could significantly increase protocol usage and Assets Under Management (AUM), which drives fee burns. The risk is execution-dependent and faces competition from other infrastructure providers within the same network.

2. Expanded MLN Token Utility (Future)

Overview: According to its documentation, the Enzyme Council DAO has planned for a while to "evolve and add more utility to the MLN token" (Tokenomics | Enzyme Documentation). While details and a timeline are unconfirmed, this could involve mechanisms like locking and staking MLN to make governance proposals, moving beyond its current primary use for paying protocol access fees.

What this means: This is neutral-to-bullish for MLN because enhanced utility, particularly staking, could create new demand sinks and reduce sell pressure. However, the documentation itself cautions that inflationary minting (up to 300,600 MLN annually for grants) is likely to exceed burn rates for years, potentially diluting any positive impact from new utility in the short term.

Conclusion

Enzyme's roadmap focuses on institutional distribution via the Canton Network while laying groundwork for stronger token economics. The project's trajectory hinges on executing these technical integrations to drive real usage, as it concurrently navigates the significant headwind of recent major exchange delistings. Will growing institutional adoption be enough to offset the liquidity and sentiment challenges from reduced exchange access?

Deep Dive

1. Joins Canton Network (22 May 2026)

Overview: Enzyme announced it has joined the Canton Foundation. This is a strategic move to integrate its infrastructure into a network designed for institutional finance, with plans to bring its Onyx and Myso products natively to the Canton Network in the third quarter of 2026.

This partnership signifies a focus on interoperability and serving regulated financial institutions. The Canton Network is a privacy-enabled, interoperable blockchain network, suggesting Enzyme is adapting its technology for environments with strict compliance requirements. The update is about preparing for deployment rather than a public code release.

What this means: This is bullish for MLN because it demonstrates serious pursuit of institutional adoption, which could significantly increase the platform's usage and the demand for its token. However, the actual technical integration and code changes are still forthcoming. (Enzyme)

2. Partners with Rayls as Launch Partner (8 May 2026)

Overview: Enzyme integrated with Rayls as a launch partner, making its Onyx (tokenized fund infrastructure) and Myso (on-chain options protocol) available on the Rayls network from its first day of operation.

This is an expansion of Enzyme's modular infrastructure to another blockchain ecosystem. It involves technical work to ensure compatibility, allowing fund managers on Rayls to access Enzyme's tools. The announcement highlights the project's strategy of being deployable across multiple networks.

What this means: This is neutral-to-bullish for MLN as it expands the protocol's potential user base and utility. A wider reach can drive more fee generation, which benefits the token's burn mechanics, but the immediate impact depends on Rayls' own adoption. (Enzyme)

3. Conducts Onyx Workshop at EthCC (2 July 2025)

Overview: The Enzyme development team held a workshop focused on Enzyme.Onyx during the EthCC conference in July 2025. This indicates ongoing, active development and refinement of its core product suite.

While not a code commit log, such workshops are where core architecture decisions and feature roadmaps are often discussed. It signals that the team is engaged with the developer community and iterating on its technology, even if the specific code changes aren't publicly detailed in the provided news.

What this means: This is neutral for MLN as it reflects continued development activity, which is essential for long-term health. However, without specific feature releases or audit results, it's a signal of progress rather than a direct catalyst. (Enzyme)

Conclusion

Enzyme's latest developments show a clear pivot towards multi-network deployment and institutional partnerships, building the rails for tokenized finance rather than publishing frequent public code updates. Will the upcoming Q3 Canton Network integration deliver the technical proof to match its strategic ambition?